462 filings
Page 18 of 24
6-K
CLLS
Cellectis S.A.
28 Jun 17
Cellectis Appoints Rainer Boehm, M.D. and Hervé Hoppenot to Board of Directors
12:00am
6-K
CLLS
Cellectis S.A.
27 Jun 17
Cellectis S.a. 6-K
12:00am
6-K
CLLS
Cellectis S.A.
26 Jun 17
Cellectis S.a. 6-K
12:00am
6-K
CLLS
Cellectis S.A.
26 Jun 17
Resolutions Within the Competence of the Ordinary Shareholders’ Meeting
12:00am
6-K
CLLS
Cellectis S.A.
23 Jun 17
Calyxt Files Registration Statement for Proposed Initial Public Offering
12:00am
6-K
CLLS
Cellectis S.A.
9 Jun 17
Cellectis S.a. 6-K
12:00am
6-K
CLLS
Cellectis S.A.
7 Jun 17
Calyxt Names Joseph B. Saluri as General Counsel & EVP, Corporate Development
12:00am
6-K
CLLS
Cellectis S.A.
16 May 17
Calyxt Launches U.S. Field Trials with University of Minnesota for Powdery Mildew-Resistant Spring Wheat Variety
12:00am
6-K
CLLS
Cellectis S.A.
10 May 17
Cellectis Patent Encompassing Broad Uses of Gene Editing Technologies Maintained by USPTO
12:00am
6-K
CLLS
Cellectis S.A.
10 May 17
Calyxt Patent Encompassing Broad Uses of Plant Gene Editing Technologies Maintained by USPTO
12:00am
6-K
CLLS
Cellectis S.A.
9 May 17
Cellectis Reports 1st Quarter 2017 Financial Results
12:00am
6-K
CLLS
Cellectis S.A.
9 May 17
Current report (foreign)
12:00am
6-K
CLLS
Cellectis S.A.
27 Apr 17
Cellectis CEO Selected as Speaker for 2017 Milken Institute Global Conference
12:00am
6-K/A
CLLS
Cellectis S.A.
26 Apr 17
Cellectis S.a. 6-K/A
12:00am
6-K
CLLS
Cellectis S.A.
25 Apr 17
Cellectis to Present at the American Society of Gene & Cell Therapy Annual Meeting
12:00am
EFFECT
CLLS
Cellectis S.A.
19 Apr 17
Notice of effectiveness
12:00am
CORRESP
CLLS
Cellectis S.A.
14 Apr 17
Correspondence with SEC
12:00am
6-K
CLLS
Cellectis S.A.
12 Apr 17
Cellectis S.a. 6-K
12:00am
UPLOAD
CLLS
Cellectis S.A.
7 Apr 17
Letter from SEC
12:00am
RW
CLLS
Cellectis S.A.
31 Mar 17
Registration withdrawal request
12:00am